Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Schöpfstr. 41, 6020, Innsbruck, Austria,
Clin Exp Nephrol. 2014 Apr;18(2):234-7. doi: 10.1007/s10157-013-0875-8. Epub 2013 Oct 16.
Lipoprotein(a) is one of the strongest genetically determined risk factors for cardiovascular disease, and patients with chronic kidney disease have major disturbances in lipoprotein(a) metabolism. Concentrations are increased and are influenced by glomerular filtration rate (GFR) and the amount of proteinuria. The reason for this elevation can be increased synthesis, as is the case for patients with nephrotic syndrome or those treated by peritoneal dialysis. In hemodialysis patients, a catabolic block is the reason for this elevation. The elevated concentrations might contribute to the tremendous cardiovascular risk in this particular population. In particular, the genetically determined small apolipoprotein(a) isoforms are associated with an increased risk for cardiovascular events and total mortality.
脂蛋白(a)是心血管疾病最强的遗传决定因素之一,患有慢性肾脏病的患者脂蛋白(a)代谢存在严重紊乱。浓度升高,受肾小球滤过率(GFR)和蛋白尿量的影响。这种升高的原因可能是合成增加,如肾病综合征患者或接受腹膜透析的患者。在血液透析患者中,这种升高是由于分解代谢受阻所致。升高的浓度可能导致这一特定人群的心血管风险极大。特别是,遗传决定的小载脂蛋白(a)亚型与心血管事件和总死亡率的增加风险相关。